Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates

Chemistry. 2024 Apr 4:e202400217. doi: 10.1002/chem.202400217. Online ahead of print.ABSTRACTCancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.PMID:38574234 | DOI:10.1002/chem.202400217
Source: Chemistry - Category: Chemistry Authors: Source Type: research